-
公开(公告)号：US20090264411A1
公开(公告)日：2009-10-22
申请号：US12371124
申请日：2009-02-13
Applicant: Victoria Elizabeth Laing , Daniel Christopher Brookings , Rachel Jane Carbery , Jose Miguel Gascon Simorte , Martin Clive Hutchings , Barry John Langham , Martin Alexander Lowe
Inventor： Victoria Elizabeth Laing , Daniel Christopher Brookings , Rachel Jane Carbery , Jose Miguel Gascon Simorte , Martin Clive Hutchings , Barry John Langham , Martin Alexander Lowe
IPC: A61K31/55 , A61K31/4365 , A61K31/381 , C07D513/04 , C07D333/52
CPC classification number: C07D495/04
Abstract: A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
Abstract translation: 一系列4,5,6,7-四氢噻吩并[2,3-c]吖庚因-8-酮衍生物及其类似物，其在2-位被取代的苯胺基部分取代，是人MEK的选择性抑制剂 （MAPKK）酶相应地在医学中有益，例如在治疗炎症，自身免疫，心血管，增殖（包括肿瘤）和伤害性疾病）中。
-
公开(公告)号：US20090186914A1
公开(公告)日：2009-07-23
申请号：US12415546
申请日：2009-03-31
Applicant: Stephen Brand , Stuart Bailey , Julien A. Brown , James A. Johnson , John R. Porter , John C. Head
Inventor： Stephen Brand , Stuart Bailey , Julien A. Brown , James A. Johnson , John R. Porter , John C. Head
IPC: A61K31/438 , C07D215/14 , A61K31/47 , A61P11/06 , A61P29/00
CPC classification number: C07D213/81 , C04B35/632 , C07C229/10 , C07C229/46 , C07C233/81 , C07C233/82 , C07C323/30 , C07C2601/04 , C07C2603/94 , C07C2603/96 , C07D213/79 , C07D213/89 , C07D311/96 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D471/04
Abstract: Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a group Ar1 L2Ar2Alk- in which: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a covalent bond or a linker atom or group; Ar2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain —CH2—CH(R)—, —CH═C(R)— or in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; X is an —O— or —S— atom or —N(R2)— group in which: Rx, Ry and Rz which may be the same or different is each a hydrogen atom or an optional substituent; or Rz is an atom or group as previously defined and Rx and Ry are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.
-
公开(公告)号：US20080226644A1
公开(公告)日：2008-09-18
申请号：US11983052
申请日：2007-11-06
Applicant: Jonathan Alexander Terrett
Inventor： Jonathan Alexander Terrett
IPC: G01N33/574 , C12N15/11 , C12N15/63 , C12N1/00 , C12Q1/68 , A61P35/00 , C07K2/00 , A61K31/7088 , A61K38/17 , C07K16/30 , A61K39/395
CPC classification number: C07K14/705
Abstract: The present invention relates to a novel polypeptide (BCMP 101) compositions comprising the polypeptide, including vaccines, and antibodies that are immunospecific for the polypeptide. The use of the polypeptide in the diagnosis, prophylaxis and treatment of cancer, in particular breast cancer is also provided.
Abstract translation: 本发明涉及包含多肽的新型多肽（BCMP 101）组合物，包括疫苗，以及针对该多肽具有免疫特异性的抗体。 还提供了多肽在诊断，预防和治疗癌症中的用途，特别是乳腺癌。
-
公开(公告)号：US07297760B2
公开(公告)日：2007-11-20
申请号：US10736227
申请日：2003-12-15
Applicant: Jonathan Alexander Terrett
Inventor： Jonathan Alexander Terrett
IPC: A61K38/00 , C07K14/00 , C07K16/00 , C07K17/00 , C07K2/00 , C07K4/00 , C07K5/00 , C12N15/00 , C12N15/09 , C12N15/63 , C12N15/70 , C12N15/74
CPC classification number: C07K14/705
Abstract: The present invention relates to a novel polypeptide (BCMP 101) compositions comprising the polypeptide, including vaccines, and antibodies that are immunospecific for the polypeptide. The use of the polypeptide in the diagnosis, prophylaxis and treatment of cancer, in particular breast cancer is also provided.
Abstract translation: 本发明涉及包含多肽的新型多肽（BCMP 101）组合物，包括疫苗，以及针对该多肽具有免疫特异性的抗体。 还提供了多肽在诊断，预防和治疗癌症中的用途，特别是乳腺癌。
-
公开(公告)号：US11702468B2
公开(公告)日：2023-07-18
申请号：US16554510
申请日：2019-08-28
Applicant: UCB Pharma, S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
IPC: G01N33/68 , G01N33/50 , G01N33/577 , C07K16/22 , C07K14/51 , C07K16/18 , A61K47/64 , C07K14/475
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , G01N33/6854 , C07K2317/76 , G01N33/50 , G01N33/577 , G01N33/68 , G01N33/6863 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
Patent Agency Ranking
公开(公告)号：US20220289832A1
公开(公告)日：2022-09-15
申请号：US17750444
申请日：2022-05-23
Applicant: UCB PHARMA, S.A.
Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.
-
公开(公告)号：US11427650B2
公开(公告)日：2022-08-30
申请号：US16124650
申请日：2019-01-21
Applicant: UCB PHARMA S.A.
Inventor： David Paul Humphreys , Emma Dave , Laura Griffin , Sam Philip Heywood
Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
-
公开(公告)号：US09828438B2
公开(公告)日：2017-11-28
申请号：US15058460
申请日：2016-07-06
Applicant: UCB PHARMA S.A.
Inventor： David Paul Humphreys , Emma Dave , Laura Griffin , Sam Philip Heywood
CPC classification number: C07K16/468 , C07K16/00 , C07K16/18 , C07K16/245 , C07K2317/24 , C07K2317/31 , C07K2317/522 , C07K2317/54 , C07K2317/55 , C07K2317/569 , C07K2317/64 , C07K2317/92
Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
-
公开(公告)号：US09550973B2
公开(公告)日：2017-01-24
申请号：US15083446
申请日：2016-03-29
Applicant: UCB PHARMA, S.A.
Inventor： Mark Ellis , David Paul Humphreys
CPC classification number: C12N1/20 , C07K16/241 , C07K16/244 , C07K2317/14 , C07K2317/20 , C07K2317/55 , C12N9/52 , C12N15/70 , C12P21/02 , C12R1/19 , Y02P20/52
Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.
Abstract translation: 包含一个或多个以下突变蛋白酶基因的重组革兰氏阴性细菌细胞：a）突变的Tsp基因，其中突变的Tsp基因编码具有降低的蛋白酶活性的Tsp蛋白或是敲除突变的Tsp基因; b）突变的ptr基因，其中突变的ptr基因编码具有降低的蛋白酶活性的蛋白酶III蛋白质或是敲除突变的ptr基因; 和c）编码具有伴侣活性和降低的蛋白酶活性的DegP蛋白的突变DegP基因; 其中所述细胞与野生型细菌细胞是同基因的，除了突变的Tsp基因和/或突变的ptr基因和/或突变的DegP基因和任选的编码目的蛋白质的多核苷酸序列。
-
公开(公告)号：US20160185761A1
公开(公告)日：2016-06-30
申请号：US14909246
申请日：2014-07-28
Applicant: UCB PHARMA, S.A.
Inventor： Florian Montel , Eric Jnoff
IPC: C07D403/06
CPC classification number: C07D403/06
Abstract: The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.
Abstract translation: 本发明涉及2-氧代-1-吡咯烷基三唑衍生物，其制备方法，含有它们的药物组合物及其作为用于增强认知功能或抵抗认知衰退的药物的用途。
-
-
-
-
-
-
-
-
-
Search Results
330
records
(took 0.026 seconds)
